Medical Oncologist Hospital Sírio-Libanês Brasília-DF. Co-Chair GU @LACOG_group. News editor @MOCBrasil. Former fellow GU oncology @sloan_kettering.
Joined March 2009
- Tweets 338
- Following 752
- Followers 716
- Likes 3,081
19 Photos and videos
Thrilled to be part of this incredible team!
The LACOG GU group has evolved significantly in recent years as a natural result of the important achievements made by our investigators and administrative staff.
We are pleased to announce the Brazil and LATAM Board members of the LACOG Genitourinary Group.
This new board term will run from 2025 to 2027, with a continued focus on the development of innovative clinical and epidemiological studies.
#LACOG
#CancerResearch
2
217
Daniel Vargas Pivato de Almeida retweeted
11 Dec 2025
Regime combinado perioperatório é aprovado pelo FDA para câncer de bexiga músculo-invasivo
Fase 3 KN905/EV-303: enfortumabe pembrolizumabe perioperatório aumentou SLE e SG no MIBC inelegível ou com recusa à QT cisplatina
@drdanielvargas @FabioSchutz78
mocbrasil.com/blog/noticias/…
1
1
122
Daniel Vargas Pivato de Almeida retweeted
3 Dec 2025
Excellent talk by @Ric_Campi on adjuvant RCC setting with thoughtful comments on multi-D strategy & shared decision making! @OncoAlert @mirrorsmed @b_szabados @Uromigos @mtsiatas @MichalisLiontos @spsutkaMD @EvanHallMD @drdanielvargas @cdanicas @PavlosMsaouel @LauraBukavinaMD
1
15
33
4,183
Daniel Vargas Pivato de Almeida retweeted
27 Nov 2025
GU Review 2025 | 27–29 nov | São Paulo online.
Actualización clave en tumores genitourinarios con referentes internacionales.
Acceso libre a la transmision virtual
geniturinariobrasil.com.br/e…
@LACOG_group @aaoncoclinica @ASCO @Marco_Care_AI @UroTarget @Blatam_urology
3
14
283
Sharing this excellent initiative led by my friends @fedelosco @mflazzaro_gu and others!
Sad for not being able to join in person!
2 Nov 2025
🎯 #UroTarget cumple 10 años. Lo que nació como una reunión es hoy una comunidad y una forma de cuidar.
Gracias @mflazzaro_gu 💙 #Oncología #UroOncología
@aaoncoclinica @ASCO @Blatam_urology
1
3
173
Daniel Vargas Pivato de Almeida retweeted
29 Oct 2025
ESMO 2025: Câncer de próstata | Dr. Daniel Vargas
Assista os destaques da #ESMO25 na área de Câncer de próstata, com apresentação do Dr. Daniel Vargas
e participação do Dr. Fabio Schutz
#MOCnaESMO #prostatecancer @drdanielvargas @FabioSchutz78
mocbrasil.com/blog/cobertura…
4
2
235
Daniel Vargas Pivato de Almeida retweeted
28 Oct 2025
ESMO 2025: Câncer de Rim e Bexiga | Dr Daniel Vargas
Nesta aula, Dr Daniel Vargas apresenta os destaques de Câncer de Rim e Bexiga da #ESMO25, com posterior discussão clínica com Dr Fabio Schutz. Não perca!
#MOCnaESMO @drdanielvargas @FabioSchutz78
mocbrasil.com/blog/cobertura…
4
3
230
Daniel Vargas Pivato de Almeida retweeted
22 Sep 2025
‼️Just Out at @JAMAOnc our Ph2 trial showing the efficacy of ICI with Chemotherapy in advanced PSCC.
Pembrolizumab Plus Platinum Chemotherapy in Advanced Penile Cancer jamanetwork.com/journals/jam…
1
2
9
913
Daniel Vargas Pivato de Almeida retweeted
29 Aug 2025
Thank you @PGrivasMDPhD for spending such a fantastic time with our group in #Brasília!
We’re deeply honored to have you with us at this unforgettable dinner. #BladderCancer
@drdanielvargas @oncoclinicas (and @crisbergerot photobombing in the corner😂)
3
8
43
7,019
Daniel Vargas Pivato de Almeida retweeted
12 Jun 2025
ASCO 2025: Câncer de próstata | Dr Daniel Vargas
Fique por dentro dos highlights da #ASCO25 em Câncer de próstata, com apresentação dos destaques pelo Dr Daniel Vargas e moderação do Dr Fernando Maluf
#MOCnaASCO @drdanielvargas @FabioSchutz78
mocbrasil.com/blog/asco-2025…
3
4
216
During the last #ASCO25 session on Prostate Cancer, presentation of updated data on #IronMan trial w/ our Brazilian PI @DrAndreFay. Last day only for the brave ones!
@LACOG_group @IRONMANregistry
1
4
301
31 May 2025
Once again meeting the @LACOG_group board members and affiliates during the @ASCO meeting. We ahead the opportunity to renew our brand mark and resilience to develop research projects in the region!
1
2
15
877
30 May 2025
Fantastic work by @PauloBergerot exploring this very important topic in LatAm.
29 May 2025
Our study reveals stark disparities in exercise referrals in LATAM
Oncologists in public 🏥 are less likely to assess, refer or guide pts on exercise due to limited resources&training
See you there! #ASCO25
@crisbergerot @fitaftercancer @GlopesMd @EnriqueSoto8 @NarjustFlorezMD
1
4
168
Daniel Vargas Pivato de Almeida retweeted
29 May 2025
Our study reveals stark disparities in exercise referrals in LATAM
Oncologists in public 🏥 are less likely to assess, refer or guide pts on exercise due to limited resources&training
See you there! #ASCO25
@crisbergerot @fitaftercancer @GlopesMd @EnriqueSoto8 @NarjustFlorezMD
1
7
25
2,457
23 May 2025
Twice in the same week, sharing the stage with the stellar @ReginaBarCar !
Now in a different county (🇨🇴) and language (🇪🇸)!!! 🤣
1
130
20 May 2025
It was a pleasure to participate in this very important initiative by @RPPGroup w/ such a stellar panel.
Prostate cancer screening in Brazil is still a challenging topic, but better tailored public policies certainly is the key to ensure an adequate approach for the adequate pts
20 May 2025
Thanks to @RPPGroup for the opportunity to share insights on prostate cancer screening with @drdanielvargas, @heinvanpoppel, and @juliaismael4!
Putting it into perspective for 🇲🇽:
⏩Most frequent cancer in men
⏩Leading cause of cancer death
⏩45% diagnosed at metastatic stage
⏩Organized programs like @OpusIncanMX lead to earlier detection of clinically significant cases
@incanMX @smumexico @SMEOMX
1
2
248
Daniel Vargas Pivato de Almeida retweeted
10 May 2025
Dica – Apixabana: resultados do estudo API-CAT
Confira, com Dr Antonio Buzaid, os resultados do estudo API-CAT, que avaliou uma nova posologia de apixabana por longo prazo em pacientes com câncer e tromboembolismo venoso
@Ro_Mariano85 @drdanielvargas
mocbrasil.com/blog/dicas/dic…
6
8
255
Daniel Vargas Pivato de Almeida retweeted
8 May 2025
Amivantamabe subcutâneo é aprovado pela ANVISA para câncer de pulmão EGFR mutado
Os estudos PALOMA-2 e 3 mostraram não-inferioridade farmacocinética e eficácia equivalente da formulação SC versus EV, com menor taxa de reações infusionais
@MarceloCorassa
mocbrasil.com/blog/oncologia…
4
3
234